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During pregnancy crucial anatomic, physiologic, and metabolic changes challenge the mother and the fetus. The placenta is a
remarkable organ that allows the mother and the fetus to adapt to the new metabolic, immunologic, and angiogenic environment
imposed by gestation. One of the physiologic systems that appears to have evolved to sustain this metabolic regulation is mediated
by peroxisome proliferator-activated receptors (PPARs). In clinical pregnancy-speciﬁc disorders, including preeclampsia, gesta-
tional diabetes, and intrauterine growth restriction, aberrant regulation of components of the PPAR system parallels dysregulation
of metabolism, inﬂammation and angiogenesis. This review summarizes current knowledge on the role of PPARs in regulating
human trophoblast invasion, early placental development, and also in the physiology of clinical pregnancy and its complications.
As increasingly indicated in the literature, pregnancy disorders, such as preeclampsia and gestational diabetes, represent potential
targets for treatment with PPAR ligands. With the advent of more speciﬁc PPAR agonists that exhibit eﬃcacy in ameliorating
metabolic, inﬂammatory, and angiogenic disturbances, further studies of their application in pregnancy-related diseases are war-
ranted.
Copyright © 2008 Fritz Wieser et al. This is an open access article distributed under the Creative Commons Attribution License,
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
1. INTRODUCTION
Peroxisome proliferator-activated receptors (PPARs) are ma-
jor regulators of lipid and glucose metabolism, inﬂamma-
tion, and angiogenesis [1–6] that allow adaptation of the
mother to the nutritional and perfusion requirements of the
fetus [3, 7, 8]. PPARs, members of the nuclear hormone
receptor superfamily, are ligand-activated transcription fac-
tors. The PPAR amino acid sequence can be divided into
ﬁve modular domains: A/B, C, D, E, and F. Domain E is
the ligand binding domain (LBD) and contains a ligand-
dependent transcriptional activation function (AF-2). Do-
main C is the DNA binding domain, formed of two typi-
cal zinc ﬁngers. PPARs activate DNA direct repeat response
elements by binding as heterodimers with retinoic acid re-
ceptor (RXR) partners [9]. There are three PPAR isotypes,
PPARα,P P A R γ,a n dP P A R β/δ, that are highly conserved
across species, with mouse, rat, and human sequences shar-
ing >80% amino acid homology [6, 10]. The conserved ex-
pression of diﬀerent PPAR and RXR isotypes in both rat
and human placentas [11] suggests that these receptors play
functional roles in placental lipid transfer and homeosta-
sis. PPARα has a wide distribution and is prominent in tis-
sues with high metabolic rates such as liver, heart, skele-
tal muscle, and kidney and in steroidogenic organs such as
the adrenals [12]. PPARγ has three isoforms (PPARγ1, γ2,
and γ3 )a n di se x p r e s s e di nb r o w na n dw h i t ea d i p o s et i s s u e ,
largeintestine,toalesserextentinimmunecells(monocytes,
macrophages, Peyer’s patches of the digestive tract), the mu-
cosaofcolonandcecum,andplacentaltrophoblasts[13–16].
PPARβ/δ is distributed in all tissues tested with particularly
high expression in placenta and large intestine [8, 17, 18].
PPARα and PPARγ a r ei n v o l v e di na d i p o c y t ed i ﬀerentiation,
lipid metabolism, insulin action, and in the regulation of in-
ﬂammatory responses [1, 5, 16], particularly involving the
macrophage [19]. PPARβ/δ is known to be involved in lipid
metabolism and inﬂammation, as well as keratinocyte diﬀer-
entiation and wound healing [5, 20, 21].
ThePPARsystemisintimately involved incardiovascular
disease,obesity, aswellaspregnancy-speciﬁcdiseases[6,22].
Over the past decade studies have shown that all three PPAR
isotypes are expressed in human placental trophoblast cells
[11]andthattheyareinvolvedintheregulationofpregnancy
physiology and its clinical complications. Physiological and2 PPAR Research
Table 1: Eﬀects of physiological and pathophysiological conditions on PPAR.
Inﬂuence on PPAR action
Conditions PPAR-action Model Reference
Diabetes Increases PPARγ in skeletal muscle Murine Park et al. [22]
Age Increases PPARγ in subcutaneous fat in older man Human Imbeault et al. [23]
Decreases PPARα in heart Murine Iemitsu et al. [24]
Hypertension Increases PPARα and γ in aorta and mesenteric arteries Murine Diep and Schiﬀrin [25]
Diet
Soy extract increases PPARα and γ in macrophages In vitro Mezei et al. [28]
High-fat diet increases adipose tissue expression of
PPARγ and induces PPARγ2 mRNA expression in liver
(obese mice)
Murine Vidal-Puig et al. [26]
Hyperlipid diet reduces PPARγ in colonic epithelium Murine Delage et al. [29]
Low-calorie diet decreases PPARγ in subcutaneous fat Human Bastard et al. [27]
Exercise
Increases PPARγ DNA binding activity in fat depots Murine Petridou et al. [30]
Increases PPARα in heart Murine Iemitsu et al. [24]
Increases PPARβ/δ in skeletal muscle Human Fritz et al. [34]
Obesity Increases of PPARγ2a n dP P A R γ2/PPARγ1 ratio in adi-
pose tissue
Human Vidal-Puig et al. [31]
Metabolic syndrome Dominant-negative mutation in PPARγ induces
metabolic syndrome
Human Savage et al. [35]
Insulin resistance (IR) Pioglitazone ameliorates IR Murine Ding et al. [33]
PPARγ Ala allele protects against hyperinsulinemia Human Jaziri et al. [32]
Vitamin A Increases PPARγ in colonic mucosa Murine Delage et al. [29]
Table 2: Eﬀects of metabolic conditions on pregnancy-speciﬁc diseases (GDM: gestational diabetes mellitus; PE: preeclampsia; IUGR: In-
trauterine growth restriction; −: reduced risk; +: increased risk).
Inﬂuence on pregnancy-speciﬁc diseases
Conditions GDM PE IUGR Reference
Diabetes — + — Ostlund et al. [36]
Advanced maternal age + + + Delbaere et al. [53] Odibo et al. [37]
Hypertension — + + Sibai et al. [38]
Optimal nutrition −−−Artal et al. [41] Saftlas et al. [43] Scholl et al. [39]
Optimal exercise −−— Artal et al. [41] Zhang et al. [44]S o r e n s e ne ta l .[ 42]
Saftlas et al. [43]
Obesity + + + Cedergren [48] Saftlas et al. [43]O ’ B r i e ne ta l .[ 47]R o s
et al. [45] Sebire et al. [46]B o d n a re ta l .[ 49]
Metabolic syndrome + + + Ray et al. [50]
Insulin resistance — + — Wolf et al. [51]
Periconceptional multivitamins — − — Bodnar et al. [52]
pathophysiological conditions that modulate the PPAR sys-
tem [22–35] inﬂuence the risk and course of preeclampsia
(PE), gestational diabetes mellitus (GDM), or intrauterine
growth restriction (IUGR) [36–53]. Some of these diseases
and factors involving the PPAR system are summarized in
Tables 1 and 2.
Inearlypregnancy,immediatelyafterembryonicimplan-
tation, major maternal physiologic changes occur in the car-
diovascular, hepatic, and endocrine systems with resultant
anatomical and metabolic modiﬁcations that serve to pro-
mote maternal immune tolerance of the conceptus and to
providethefetuswithitsincreasednutritionalneeds[54,55].
Metabolic changes (including increased availability of glu-
cose, low density lipoprotein, and fatty acids) increased in-
sulin resistance and altered amino acid metabolism, im-
munologic, and hematologic changes (including an increase
in plasma volume). Establishment of a thrombophilic state
and extensive placental and decidual angiogenesis are ob-
served in pregnancy, and these changes require a complex
activation of regulating mediators [56–58].
Pregnancy complications result when the mother and/or
fetus fail to adapt to these new metabolic, angiogenic, and
thrombogenic challenges. Women with preexisting com-
promise to their vascular homeostasis, such as underlyingFritz Wieser et al. 3
Table 3: PPAR knock out models and placental pathology (PRIP: peroxisome proliferator-activated receptor-(PPAR) interacting protein;
RAP 250: nuclear receptor-activating protein 250).
PPAR knockout model Placental pathology Lethality Reference
PPARα No signiﬁcant eﬀect on placentation 20% Yessoufou et al. [76]
PPARβ/δ Poor placentation >90% Barak et al. [77]
PPARγ Poorly developed labyrinth 100% Barak et al. [15] Kubota et al. [82]
PPARγ coactivator PRIP Reduced spongiotrophoblast layer 100% Zhu et al. [79]
PPARγ coactivator RAP250 Reduced spongiotrophoblast layer 100% Antonson et al. [80]
RXRα or β Lack of labyrinth zone 100% Sapin et al. [81]
hypertension, diabetes mellitus, or metabolic syndrome,
have a signiﬁcantly increased risk of developing pregnancy
complications (see Table 2). Placenta-associated complica-
tions also can lead to impaired growth or fetal demise
[59, 60]. These placental conditions share vasculopatholog-
ical mechanisms in common with atherosclerosis and rep-
resent early markers for maternal risk of cardiovascular dis-
ease[61,62]andhypertension[61,63,64].Curiously,aprior
history of preeclampsia appears to confer protection against
the future development of endometriosis and some cancers
[65, 66].
PPARs can be activated by natural ligands, like prosta-
glandins (PGs), fatty acids, and their derivatives, as well as
by synthetic ligands. PPAR medications have been devel-
opedand discovered to be relatively safe drugs with bene-
ﬁts in multiple disease states including diabetes and cardio-
vascular disease [67]. Fibrate drugs used to treat hyperlipi-
demia, and thiazolidinedione drugs used to treat type 2 di-
abetes are potent and relatively speciﬁc ligand activators of
PPARα and γ, respectively, and are widely used clinically
[68,69].Anumberofnaturally-occurringPPARligandshave
been identiﬁed, including long-chain fatty acids (C16 and
greater), eicosanoids such as 8(S)-HETE (PPARα)a n d9 -
and13-HODE (PPARγ), and PGs such as PGA1,which binds
to PPARα,P P A R β/δ, and 15-deoxy-delta12,14-prostaglandin
J2(15dPGJ2), which in turn binds to PPARγ [70–72]. Both
the expression of PPAR and the production of their poten-
tial ligands are altered during pregnancy and its related dis-
eases. We postulate that pathologic diversion of fatty-acid
metabolism away from the production of eicosanoid ligands
in preeclampsia and gestational diabetes might be corrected
using synthetic ligands.
2. PPARs IN TROPHOBLAST INVASION AND
PLACENTAL DEVELOPMENT
In ﬁrst trimester, human placental bed biopsies, PPAR-γ is
expressed predominantly in invasive trophoblasts, whereas
in the second-trimester PPARγ is expressed in the columns
of anchoring villi and cytotrophoblasts [73, 74]. In the
third trimester, PPARγ principally localizes to extravillous
cytotrophoblasts (EVCT) and villous syncytiotrophoblasts
[75], where it appears to regulate placental hormone pro-
duction and secretion. Although the focus of this review is to
summarize ﬁndings on PPAR/RXR heterodimers in human
placentation, much of the direct evidence for a role of these
receptors in trophoblast invasion and placental development
has emerged from studies in knockout mouse models. This
topic is reviewed comprehensively in Schaiﬀ et al. [3], and is
summarized brieﬂy here and in Table 3 [76–81].
PPARγ/RXRα heterodimers play a key regulatory role in
murine placental development. PPARγ deﬁciency was shown
to interfere with terminal trophoblast diﬀerentiation and
placental vascularization [78]; embryos without this gene
showmassiveplacentaldefectsthatcanberescuedbyrestora-
tion of the trophoblast PPARγ gene via tetraploid chimeras
[15]. Deletion of RXRα and RXRβ also leads to embryo
lethality [15, 81, 83]. Both PPAR-interacting protein (PRIP)
and nuclear receptor-activating protein 250 (RAP250) en-
codenuclearreceptorcoactivatorsthatassociatewithPPARs,
RXRs, and other nuclear receptor proteins. Genetic disrup-
tion of PRIP or RAP250 in mouse models results in em-
bryonic lethality at postconception days 11.5 and 13.5, re-
spectively [79, 80]. Placentas of PRIP (−/−) and RAP250
(−/−) embryos exhibited dramatically reduced spongiotro-
phoblast and labyrinth layers as well as failure of blood vessel
maturation in the region bordering the spongiotrophoblast
[79, 80].
In addition to placentation per se, PPARγ appears to play
an important role in the uterine preparation for embryonic
implantation.Peetersetal.demonstratedthatPPARγ ligands
reduced the production of the endometrial angiogenic fac-
tor VEGF, and postulated that this pathway might inﬂuence
earlyembryonicvascularization[84].Bycontrast,PPARγ ag-
onistsinduceangiogenesisincardiacmyoﬁbroblasts,smooth
muscle cells, and macrophages [85–87]. Recent preliminary
data by our lab and others suggest that the PPARγ system
also stimulates VEGF expression in trophoblast (JEG-3) cells
(Depoix et al., unpublished).
The functional role of PPARγ activity is well studied in
trophoblast physiology (Table 4). PPARγ agonists inhibit in-
vasion of cultured EVCT isolated from human ﬁrst-trimester
placenta, whereas PPARγ antagonists promoted EVCT inva-
sion and repressed the PPARγ agonist-mediated eﬀects [78].
PPARγ controls mucin (MUC)-1 transcription and regu-
lates maternal-fetal transport in mouse models [88]. More-
over, PPARγ and RXRα play a role in human chorionic go-
nadotropin (hCG) expression, trophoblast diﬀerentiation,
and regulation of fatty acid transport and storage in human
placental trophoblasts [89, 90]. PPARγ diminishes leptin-
induced inﬂammatory responses in the human placenta [91]
and inhibits PAPP-A expression [92].4 PPAR Research
Table 4: PPAR action in trophoblast development and placental function (MUC-1: mucin-1; EVCT: extravillous cytotrophoblast; hCG:
human chorionic gonadotropin; Th2 T-helper 2 cell).
PPAR action in trophoblast development and placentation
PPAR PPAR action Model Reference
PPARγ
Inhibits EVCT invasion In vitro Fournier et al. [78]
Promotes trophoblast diﬀerentiation hCG secretion In vitro Tarrade et al. [89]
Induces hCG production In vitro Schild et al. [93]
Antiinﬂammatory In vitro Lappas et al. [91]
Regulates fatty acid transport In vitro Schaiﬀ et al. [90]
Increases VEGF expression In vitro Depoix, unpublished
Terminal diﬀerentiation, placental vascularization Murine Barak et al. [15]
Controls MUC-1 expression Murine Shalom-Barak et al. [88]
Stimulates trophoblast maturation Murine Asami-Miyagishi et al. [94]
Modulates placental lipid metabolism Murine Capobianco et al. [95]
PPARβ/δ Promotes placental development Murine Nadra et al. [8]
PPARα Regulates placental lipid transfer Murine/Human Wang et al. [74]
PPAR action in pregnancy
PPARγ
Antiinﬂammatory In vitro Lappas et al. [96]
Involved in inﬂammatory control and remodeling in the placenta In vitro Marvin et al. [97]
Increased circulating PPARγ activators in normal pregnancy In vitro/human Waite et al. [73]
Decreases in fetal membrane with labor Human Dunn-Albanese et al. [98]
PPARβ/δ Increases in amnion with labor Human Berry et al. [99]
PPARα Stimulates Th2 cytokine pattern during pregnancy Murine Yessoufou et al. [76]
Declines in choriodecidua with labor Human Berry et al. [99]
Regulation of PPARγ in human placental tissues is
thought to occur through natural ligands (e.g., 15dPGJ2, 9-
HODE, 13-HODE, and 15-HETE) through direct binding to
the receptor’s ligand binding pocket [11, 100]. These ligands
are likely to be synthesized locally within the placenta. Fur-
thermore, crosstalk between the mitogen-activated protein
kinase (MAPK) p38 and PPARγ occurs within cultured tro-
phoblast cells [101]. PPARγ d e c r e a s e sI G F I Is e c r e t i o na n di s
thought to inhibit trophoblast invasion via the PAPP-A cas-
cade [92].
In young PPARα knock out mice, no major phenotypic
diﬀerences of gross pathology of internal organs were de-
scribed [76, 102]. However, disturbance of the Th1/Th2 T-
lymphocyte ratio, rather than placental malformation, is
thought to be responsible for an increased abortion rate
(20%) in PPARα null mice. During normal pregnancy Th1
cytokines are downregulated and Th2 cytokines are upregu-
lated [103].
The third distinct PPAR, PPARβ/δ also is essential for
placentation as demonstrated in PPARβ/δ knockout mice
(Table 3)[ 77], and is involved in the regulation of implanta-
tioninotheranimalmodels[17,104,105].Theimplantation
of cultured embryos is enhanced by PPARβ/δ activation and
this receptor even has been postulated as a novel therapeutic
target to improve clinical IVF outcomes [104]. PPARβ/δ is
induced during decidualization of the implantation site and
requires close contactwith the blastocyst. PPARβ/δ null mice
diebetween9.5to10.5embryonicdaysduetoabnormalcell-
cell communication at the placental-decidual interface [8].
Together these data suggest that PPARs are required not
only for trophoblast invasion and diﬀerentiation but also for
establishment of the placental maternal-fetal transport.
3. PPARS AND PREGNANCY
Based on its regulatory functions and known eicosanoid lig-
ands, PPARγ has emerged as an excellent candidate to play a
role in the regulation of maternal metabolism, maintenance
of uterinequiescence,and onsetof laborbyregulatingproin-
ﬂammatory cytokines and prostaglandins (Table 4). Normal
pregnancy is accompanied by changes in lipid and glucose
metabolism, but further dysregulation of these pathways can
lead to pregnancy complications such as PE or GDM. Hence,
PPAR regulators of these metabolic pathways might be ex-
pected to be important in human pregnancy.
Some of our initial studies in this ﬁeld were designed to
screen for potential activators of PPARγ in the circulation of
pregnant women. Human choriocarcinoma JEG-3 cells were
transfectedwithperoxisome-proliferatorresponsivereporter
plasmids; and pooled sera from pregnant and nonpregnant
women were added to the cell culture medium [73]. Per-
oxisome proliferator responsive element (PPRE) luciferase
reporter activation was dramatically increased by sera from
pregnant women compared to nonpregnant women (Fig-
ures 1 and 2). We showed that PPARγ (and to some ex-
tent PPARα) activity is increased from the earliest stages of
pregnancy (Figure 2). The ﬁndings suggested that circulat-





























Figure 1: JEG-3 cells were transfected with PPRE-luciferase re-
porter vectors and treated with pooled sera (10%) from non-
pregnant (NP), pregnant (P) and preeclamptic (PE) women. Lu-
ciferase acitivity, relative to cells treated with 10% dextran charcoal-
shipped fetal calf serum (DCSS), is reported on the ordinate.
present throughout the course of gestation. We hypothesized
that activation of PPARγ by sera of pregnant women is a
regulatory adaptation of the maternal organism to increased
lipid and glucose loading in pregnancy [73].
It also has been hypothesized that PPARγ activation
regulates uterine quiescence by inﬂuencing Nuclear Factor-
K a p p aB( N F κB) and cyclooxygenase (COX-2) expression
[96, 97, 106]. Reciprocal expression of PPARγ and (COX)-
2 in human term placenta suggests a role of the PPAR sys-
tem in the initiation of labor [98]. Under conditions of
high PPARγ expression, antiinﬂammatory actions dominate;
however, with onset of labor PPARγ levels drop and COX-
2 concomitantly increases in the fetal membranes [98]. Ele-
vatedCOX-2activityinthehumanamnionisobservedinthe
settings of term and idiopathic preterm labor, contributing
to the generation of uterotonic prostaglandins (PGs), which
are known to participate in parturition [107]. PPARγ ligands
have been shown to antagonize NF-κB activation and reduce
inﬂammatory cytokine gene expression (IL-1β, IL-6, IL-10
and TNF-α) and COX-2 [108]. Both natural (e.g., 15dPGJ2)
and synthetic ligands (e.g., troglitazone) were shown to have
anti-inﬂammatory eﬀects in human gestational tissues, sig-
niﬁcantly decreasing basal and LPS-stimulated PGE2 and
PGF2α release from placenta and amnion [108]. PGF2α ,
also a marker of oxidative stress, is increased in women
with preeclampsia [109]. Given the inﬂammatory changes
observed in pregnancy-speciﬁc diseases, a potential role of
PPAR agonist treatment has been entertained for the treat-
ment of PE, GDM, and other pregnancy-speciﬁc diseases
such as the prevention of preterm labor [96].
PPARα and β/δ also play a role in maintaining pregnancy
and parturition. PPARα and β/δ are expressed in the am-
nion, choriodecidua, and villous placental tissues. Data from
PPARα knockout mice suggest that PPARα maintains preg-
nancy by stimulating a Th2 cytokine response [76]. In nor-
mal pregnancy, expression of PPARα declines in the chori-
odecidua with the onset of labor [99]. By contrast, PPARβ/δ
expression,whichistemporallyupregulatedbetweentheﬁrst
and third trimester of pregnancy [99], increases further in
the amnion coincidental with the onset of labor [99].




























Figure 2: PPARγ activation is present throughout the course of
normal pregnancy. All serum samples were collected from the same
subject and PPRE-luciferase reporter experiments were performed
using 10% serum as described in Figure 1. Luciferase activity was
normalized to DCSS to determine relative activation. Black hori-
zontal bar represents the level of signaling seen with 10% serum
from the same woman six weeks after delivery.
Few studies have elucidated substantial risk of PPAR ag-
onists during pregnancy in animal models, but these drugs
carry a “C” classiﬁcation from the FDA. For example, rosigli-
tazone did not damage blastocyst development in vitro or
harm mouse fetuses when given during murine pregnancy
[110]. While the use of rosiglitazone during pregnancy is
generally considered to be safe [110]; more data need to be
acquired before these drugs can be recommended.
4. PPARs AND PREGNANCY-SPECIFIC DISEASES
Failure of metabolic adaptation to pregnancy can result in
pregnancy-speciﬁc complications such as PE and GDM. We
and others have postulated that angiogenic factors and cy-
tokinesthatleadtopathologicalgestationalchangesarelikely
to be regulated by the PPAR system (Table 5).
4.1. PPARsandpreeclampsia
PE is a multifactorial, pregnancy-related disorder that is de-
ﬁned by new-onset hypertension and proteinuria after 20
weeks of gestation [117]. PE is a common cause of mater-
nal and infant morbidity and mortality worldwide, and is
responsible for about 20% of pregnancy-related maternal
deaths in the US [118]. Women with PE have increased in-
sulin resistance as well as hypertriglyceridemia relative to
normal pregnant women [119]. To date, no eﬀective treat-
ment has been found that either prevents or reverses the de-
velopment ofthe disease. Modern concepts ofPE pathophys-
iology invoke a two-stage process. The ﬁrst stage is believed
to be initiated by impaired trophoblast invasion and abnor-
maluterinevesselremodeling.Thesecondstageispostulated
to result from circulating factors claimed to be derived from
the ischemic placenta that stimulate an inﬂammatory activa-
tion of maternal vascular endothelial cells. PE presents clin-
ically in the second or third trimester, however, fundamen-
tal inﬂammatory and angiogenic biomarkers in the serum
are detectable as early as the ﬁrst trimester in women with
PE. Elevated concentrations of IL-2, TNFα, and sVEGFR-16 PPAR Research
Table 5: PPAR in pregnancy-speciﬁc diseases.
PPAR PPAR-action Disease Model Reference
PPARγ
Reduced circulating PPARγ activators in serum from
women with PE
PE In vitro Waite et al. [111]
Placental 15dPGJ2level are decreased in diabetes GDM Murine Capobianco et al. [95]
Association of PPAR-γ2 Pro12Ala with weight gain GDM Human Tok et al. [112]
Placental 15dPGJ2levels are decreased GDM Human Javerbaum et al. [113]
Decreased Hydatidiform mole Human Capparuccia et al. [114]
Decreased Choriocarcinoma Human Capparuccia et al. [114]
Placental PPAR expression is not involved IUGR Human Rodie et al. [115]
Association of PPAR-γ2 Pro12Ala polymorphism Preterm birth Human Meirhaeghe et al. [116]
PPARα Lack of PPAR-α upregulates Th1 cytokines Abortion/neonatal mortality Murine Yessoufou et al. [76]
NP P PE
PPARγ (52KDa)
Figure 3: Immunoblot of JEG-3 cells treated with pooled sera
(10%) from nonpregnant (NP), pregnant (P), and preeclamptic
(PE) women. Cell lysates were analyzed using a speciﬁc mouse anti-
human PPARγ monoclonal antibody. Equal amounts of protein
(50μg) were loaded into each lane. Factors in pregnant serum up-
regulate JEG-3 PPARγ expression. A decrease in PPARγ protein was
observed in cells exposed to PE sera (PE) compared to sera from
normal pregnant women (P).
and reduced concentrations of PlGF, IGFBP-1, and HLA-G




Relevant to this review are hypertension, diabetes, and high
(>29) body mass index (BMI) [47, 124, 125]. Black race also
appears to be a risk factor for PE [126] although this may
be confounded by increased rates of the above risk factors.
Key inﬂammatory and angiogenic pathways involved in the
pathogenesis of PE are regulated by the PPAR system, which
itself is inﬂuenced by environmental and genetic factors. We
believe that exogenous and endogenous lipid regulators of
PPAR play a role in maternal metabolism and immune func-
tionin normal and pathological pregnancies. For example,
dietary factors and physical activity that modulate the PPAR
system have been shown to reduce the risk and course of PE
(Table 2).
Similarly, genetic variations in the PPARγ gene have
been proposed to modify the risk of PE. For example, the
Pro467LeumutationofPPARγ [127–129]isadominantneg-
ative mutant resulting from a C-to-T transition in exon 6.
A report of two individuals (one woman, one man) with
this mutation showed that they developed type 2 diabetes
at young ages (26 and 27 years at diagnosis), as well as
early hypertension (37 and 27 years at diagnosis). Intrigu-
ingly, the woman had two pregnancies, both of which were
complicated by severe PE. The Pro12Ala polymorphism oc-
curs in PPARγ2[ 130], a second isoform of PPARγ that is
expressed mainly in adipose tissue. This mutation is the
result of a C-to-G transversion in exon B. This is by far
the most studied allelic variation in any PPAR, and oc-
curs at a rate of about 12% in the Caucasian US popula-
tion. While the resulting phenotype is highly diverse and
even apparently contradictory, it appears that the penetrance
of this mutation is inﬂuenced by other genetic, environ-
mental, ethnic, and gender diﬀerences. The studies gen-
erally agree that the presence of the Ala allele is associ-
ated with increased BMI, an independent risk factor for
PE. Thus, this polymorphism is a candidate aﬀecting preg-
nancy outcome. Preliminary data of a study on the PPAR
gene variations (in PPAR gene) showed no association with
PE or severity of PE in a Finnish population [131]. Fur-
ther studies on the association of PPAR α, β,a n dγ gene
variations of mothers and oﬀspring and pregnancy-speciﬁc
diseases need to be performed in diﬀerent ethnic popula-
tions.
PE is marked by hyperlipidemia, and is characterized by
a state of oxidative stress. Circulating lipids in PE women
are more highly oxidized, and oxidized low-density lipopro-
teins(oxLDLs),inparticular,arehighlyelevated[132].Given
the circulating plasma lipid disturbances in PE, our group
performed experiments comparing sera from normal and
PE patients. We found that serum from women with severe
PE had reduced levels of PPAR activating lipids compared
with serum of parity and gestational age-matched women
and also diminished the expression of PPARγ in trophoblast
cells(Figures1and3)[111].ThereductionoftranscriptionalFritz Wieser et al. 7
activity observed in preeclamptic women’s sera was shown
for PPARγ and PPARα,h o w e v e rn o tf o rP P A R β/δ or RXR.
The reduction in potential circulating PPAR activatorswas
observed weeks and sometimes months before the onset of
maternal symptoms and clinicaldiagnosis of PE [133]. Our
results are consistent with other clinical evidence that an-
tiinﬂammatory regulation is challenged and further com-
promised in the maternal syndrome of PE. Normal preg-
nancy manifests as a physiologic inﬂammatory state pos-
tulated to be tolerated to serve the nutritional needs of
the fetus, whereas, in PE regulatory inﬂammatory mecha-
nisms are excessively ampliﬁed, leading to vascular damage
in the mother [133]. In this “hyperinﬂammatory” state of
PE [134], the cytokines TNFα and IL-1β which are typi-
callycontrolledbytheNF-κBpathwayinanegative-feedback
loop with PPAR, are elevated [26, 60, 119]. Elevated in-
ﬂammatory parameters in PE accompany altered levels of
PG metabolites and circulating fatty acids. As noted, PG
metabolites as well as fatty acids are important ligands of the
PPAR system [135]. PG metabolism is altered during nor-
mal pregnancy with levels of vasorelaxants suchas prostacy-
clin increasing, whereas vasoconstrictive prostaglandin lev-
elstend to be suppressed [136]. Failure of these alterations
have been suggested to lead to pregnancy complications
(e.g., PE) [137]. For example, PGF2α, which itself is stimu-
lated by factorsin the plasma of women with PE [138], can
inhibit PPARγ eﬀects [135]. Levelsof circulating free fatty
acids are in the normal range duringmost of pregnancy, but
rise dramatically during the ﬁnal weeks of pregnancy and
drop precipitously at term [136]. In PE these levels are in-
creased from 20 weeks’ gestation [133, 139]. We postulate
that altered PG metabolism in this setting [138] results in
decreased PPARγ ligation and subsequent cytokine activa-
tion. If this proposal is supported by more data, the use of
PPAR ligands might be proposed to ameliorate symptoms
such as hypertension and inﬂammation. Unfortunately, at
present, the mechanism and site of this salutary of PPAR lig-
and eﬀect remain unknown in pregnancy, confounded by
PPAR expression in many cell types, including endothelial
cells.
4.2. PPARsandgestationaldiabetes
During normal pregnancy, maternal lipid, and glucose
metabolism is profoundly altered [140]. The developing fe-
tususesglucoseasitspredominantenergysource,whichputs
a continuous demand on the mother to provide this sub-
strate [141]. This constant need for glucose results in fre-
quent hypoglycemia and postprandial hyperglycemia during
normal pregnancy [141]. Problems with energy metabolism
such as GDM are not uncommon and are often observed
in susceptible women at this time. GDM is deﬁned as any
degreeof glucose intolerance with onset or ﬁrst recognition
during pregnancy. In women with GDM, defective β-cells
function cannot adequately compensate for free fatty acid-
mediated insulin resistance [142]. As elsewhere in our so-
ciety, the incidence of obesity, diabetes, and gestational di-
abetes mellitus are increasing in the pregnant population
[143]. In the United States, the incidence of obesity among
pregnant women ranges from 18.5% to 38.3% [144]; obesity
comprises a major risk factor for GDM [145]. Morphologi-
cal changes have been identiﬁed in the syncytiotrophoblast,
cytotrophoblast, trophoblastic basement membrane, and fe-
tal vessels within the placentae of these cases [146]. GDM
is associated with several severe neonatal complications
(such as macrosomia, brachial plexus palsy, premature de-
livery, IUGR, and intrauterine death) and maternal birth in-
juries also are common [125, 147]. Furthermore, GDM has
emerged as a risk factor for the development of diabetes mel-
litustype2(DM2)andcardiovasculardiseaseinlaterlifeand
shares a number of epidemiologic, pathophysiologic, and ge-
netic characteristics with DM2 [148]. GDM also has detri-
mental eﬀects on the postnatal infants [149].
The PPAR system regulates the metabolic and pathways
involved in the establishment of GDM. PPAR-agonists have
antidiabetogenic, antiinﬂammatory, and antioxidant eﬀects,
which are all potentially beneﬁcial in the treatment of GDM
[5].
Environmental factors, such as diet and exercise and ge-
netic factors inﬂuence PPARα, γ activity [130, 150]a sw e l l
as the risk for insulin resistance and GDM (Table 2). Exer-
cise activity initiated prepregnancy was shown to reduce the
riskofGDManditscomplications[40,41,44,151,152].Nu-
tritional counseling, moderate physical exercise, weight loss,
and diet are successful therapies in some women with GDM,
improving glycemic control, reducing the incidence of LGA
infants, and decreasing the need for cesarean deliveries for
cephalopelvic disproportion [41, 153].
Candidate genes for GDM risk include TNFα, β3
adrenoreceptor (ADRB3), and PPARα and γ. The PPARγ
Pro12Ala polymorphism was not associated with increased
insulin resistance in Turkish women with GDM, how-
ever it was associated with weight gain [112]. The PPARγ
coactivator-1alpha (PGC-1) polymorphism also failed to be
associated with the development of GDM [154]. More stud-
ies on the association of various genetic PPARα and γ vari-
ants and GDM in diﬀerent ethnic populations will be of in-
terest.
15dPGJ2 is a potent antiinﬂammatory agent that re-
presses the expression of a number of inﬂammatory genes
and regulating factors including the transcription factor NF-
κB[ 33, 108]. The concentration of 15dPGJ2 was reduced
in placentae from diabetic rats (Table 5)[ 95]. Placental
15dPGJ2 was noted to be diminished in women with ges-
tational and pregestational diabetes when compared to con-
trols, whereas levels of nitric oxide (a stimulator of placental
invasiveness, diﬀerentiation, and proliferation) were higher
in term placental explants from diabetic patients when com-
pared to controls [113]. As PPARγ can prevent nitric ox-
ide overproduction in placenta from pregestational diabetic
women [113], it may have the potential to improve fetal out-
come in this condition.
Sulfonylurea agents including gliumepiride and gliben-
clamide exhibit PPARγ activity [155]. A randomized con-
trolled trial to test the eﬀectiveness and safety of the sul-
fonylureaagentglyburideinthemanagementofwomenwith
GDM showed similar eﬃcacy to insulin treatment [156].
Both the insulin- and glyburide-treated women were able to8 PPAR Research
achieve satisfactory glucose control and had similar perinatal
outcome [156].
4.3. PPARsandotherpregnancy-speciﬁcdiseases
Trophoblast research has emphasized the similarities be-
tween the proliferative, migratory, andinvasive properties
of placental cells and those of cancer cells [157]. PPARγ,
PPARβ/δ, and RXR appear to be linked to gestational tro-
phoblastic neoplasms, conditions associated with malignant
trophoblast behavior [114]. PPARγ agonists inhibit invasion
of normal extravillous cytotrophoblast isolated from human
ﬁrst-trimester placenta, and PPAR activity has been shown
to be downregulated in trophoblastic diseases including hy-
datidiform mole and choriocarcinoma [114].
PPARγ has an eﬀect on fetal and placental size inﬂuenc-
ingintrauterinegrowth.Inanintrauterinegrowthrestriction
(IUGR) model, glucocorticoids inhibited fetal and placental
growth partly by suppression of PPARγ in the labyrinth zone
of the placenta [158]. Activation of PPARγ in the labyrinth
trophoblasts is hypothesized to induce angiogenic factors
and stimulate the growth of fetal blood vessels, thereby pro-
moting placental growth. However, treatment of pregnant
mice with rosiglitazone led to reduced thickness of the spon-
giotrophoblast layer and the surface area of labyrinthine vas-
culature, and it altered expression of proteins implicated in
placental development [159].
In vitro and in vivo experiments as well as animal models
studies suggest a link between the PPAR system and gesta-
tional duration, preterm labor, and birth weight [116]. Vari-
ations in the PPAR genes inﬂuence other pregnancy-related
mechanismsincludingbirthweightandgestationalduration.
In an Irish population, the PPARγ Ala12 allele was associated
with shorter gestational duration [116].
PPAR ligands regulate apoptotic mechanisms involved
in rupture of the fetal membranes and may play a role
in preterm delivery, a condition associated with increased
risk of neonatal sepsis and newborn trauma [160]. 15d-
PGJ2induced morphological characteristics of apoptosis
within 2 hours in an amniotic cell line [160]. In addition,
ciglitizone also induced apoptosis, whereas rosiglitazone had
no eﬀect on cell viability [160]. Prevention of apoptosis may
have therapeutic potential in preterm labor and premature
rupture of the membranes and necessitates further investiga-
tions.
Interestingly, PPARα deﬁciency is associated with mis-
carriage, neonatal mortality, and a shift from Th2 to a Th1
cytokine phenotype [76]. Th1 predominant immunity is
closely associated with inﬂammation, endothelial dysfunc-
tion, andpregnancycomplications.Forexample,interferonγ
is signiﬁcantly reduced in the spleens of PPARα null mice
[76]. Twenty percent of PPARα knockout mice aborted, and
oﬀspring of PPAR-α null mice exhibited increased neonatal
mortality (13.3%).HoweverthemechanismwherebyPPARα
induces a Th2 phenotype shift remains to be determined.
PPARγ ligands also were shown to decrease production of
inﬂammatory ligands in activated macrophages and T cells
and to induce a shift from Th1 to Th2 cytokine phenotype
[161, 162].
5. CONCLUSIONS
PPARs are involved in trophoblast invasion, placental devel-
opment,parturition,andpregnancy-speciﬁcdiseases,partic-
ularly PE and GDM. The role of the PPAR system in preg-
nancy under physiologic and pathologic conditions has re-
mained partly unclear due to lack of knowledge about en-
dogenous PPAR ligands. Pharmacological ligand research is
ahead of the identiﬁcation of physiologic ligands. Partially
characterized inﬂammatory, angiogenic, and metabolic dis-
turbances in pregnancy-related diseases suggest that these
syntheticPPARagonistsmaybeofpotentialuseinthesecon-
ditions. Ongoing basic studies have elucidated the metabolic,
antiinﬂammatory, and angiogenic beneﬁts of PPARα/β/δ
and PPARγ/β/δ dual agonists and PPAR pan agonists for
treatment purposes. However, some experimental and clin-
ical data have uncovered unfortunate side eﬀects of PPAR
ligands, including cancer progression and increased cardiac
e v e n tr a t e s .N e wg e n e r a t i o n so fP P A Rm o d u l a t o r sa r eu n d e r
developmentandthesepromisetobemorereceptor-speciﬁc,
and hopefully will activate only a speciﬁc subset of target
genes and metabolic pathways to reduce untoward side ef-
fects. The potential role of PPARs in regulation of inﬂam-
mation and angiogenesis is intriguing and warrants further
studies. We submit that PPAR agonists may become bene-
ﬁcial drugs for pregnancy-speciﬁc diseases, once their risks
have been fully evaluated.
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